[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"renovascular-hypertension\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:renovascular-hypertension":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":33,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100633844","vascular-complications-after-kidney-transplantation-100633844",false,"NCT07531966","Vascular Complications After Kidney Transplantation","Vascular Complications After Kidney Transplantation: A Prospective National Multicenter Study - The DAN-PTRAIII Study","DAN-PTRAIII","Inclusion Criteria:\n\n1\\. At least one of the following clinical criteria (1 or 2) must be fulfilled:\n\n1. Graft dysfunction, defined by at least one of the following:\n\n   * Acute reduction in estimated glomerular filtration rate (eGFR) \\>15% on two consecutive measurements at least 2 weeks apart, with other causes excluded (rejection, obstruction, infection).\n   * eGFR \\\u003C50% of the expected value 30 days after kidney transplantation of unknown cause.\n   * Decline in eGFR \\>30% after initiation of an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker.\n2. Persistent resistant hypertension for more than 6 weeks after kidney transplantation, defined as:\n\n   * 24-hour ambulatory systolic blood pressure \\>130 mmHg despite treatment with at least three classes of antihypertensive medication at maximally tolerated doses (including diuretics, if tolerated).\n\nTogether with at least one of the following radiological criteria:\n\n1. CT or MR angiography demonstrating a lumen reduction ≥50%.\n2. Doppler ultrasound showing:\n\n   1. Peak systolic velocity in the renal artery ≥200 cm\u002Fs and a renal renal ratio (velocity at stenosis \u002F velocity in distal artery) \\>4.\n   2. Acceleration time \\>70 ms in intrarenal arteries.\n\n2\\. In cases of strong clinical suspicion of a vascular complication where CT or MR angiography cannot reliably exclude graft artery or vein stenosis, patients may be referred for confirmatory invasive investigations.\n\nBefore PTA, catheter-based angiography and translesional pressure measurements are performed to confirm whether the patient meets the radiological eligibility criterion for PTA:\n\n1. Stenosis ≥70%.\n2. Stenosis 50-69% if at least one of the following criteria is met:\n\n   * Mean translesional pressure gradient ≥10 mmHg.\n   * Systolic pressure gradient ≥20 mmHg.\n   * Renal Pd\u002FPa ≤0.8.\n   * If pressure measurements cannot be obtained, treatment is based on the operator's clinical judgement.\n\nExclusion Criteria:\n\n1. Inability to provide informed consent.\n2. Concurrent biopsy demonstrating rejection requiring treatment.\n3. Pregnancy.\n4. Previous PTA of the same vessel.\n5. Patients unable to tolerate any form of antithrombotic therapy and therefore not eligible for stent placement.","ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","10 Years","OBSERVATIONAL","* To determine the incidence of arterial inflow problems and venous outflow problems as causes of impaired renal function and\u002For treatment-resistant hypertension after kidney transplantation, when all kidney-transplant recipients in Denmark are evaluated according to uniform, well-defined clinical criteria.\n* To investigate the efficacy and safety of catheter-based balloon treatment (percutaneous transluminal angioplasty, PTA) for these vascular complications, of which transplant renal artery stenosis is by far the most common.\n* To assess whether novel imaging and functional diagnostic methods can predict treatment response.",[26,27,28,29,30,31,32],"Kidney Transplant Recipient","Kidney Transplant; Complications","Transplant Renal Artery Stenosis","Renovascular Disease","Renal Transplant Graft Failure","Renovascular Hypertension","Heart Failure",[27,28,34,35],"renovascular disease","Percutaneous transluminal angioplasty","RECRUITING","2026-05-26",{"date":39,"type":40},"2026-05-27","ACTUAL",{"date":42,"type":40},"2026-05-22",{"date":44,"type":21},"2031-06-01",{"name":46,"class":47},"University of Aarhus","OTHER",3,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":48},"100503403","effects-of-percutaneous-transluminal-renal-angioplasty-of-atherosclerotic-renal-artery-stenosis-in-high-risk-patients-100503403","NCT05834803","Effects of Percutaneous Transluminal Renal Angioplasty of Atherosclerotic Renal Artery Stenosis in High-Risk Patients.","Effects of Percutaneous Transluminal Renal Angioplasty of Atherosclerotic Renal Artery Stenosis in High-Risk Patients - a Danish Nationwide Randomized Sham-Controlled Study.","DAN-PTRAII","Inclusion Criteria:\n\n1. One or more severe atherosclerotic renal artery stenoses defined as a stenosis ≥70% by catheter-based angiography.\n2. In addition, at least one of the following high-risk clinical syndromes:\n\n   1. Resistant hypertension with average 24-hour ambulatory systolic blood pressure ≥150 mmHg despite ≥3 antihypertensive drugs including a diuretic, if tolerated, and each prescribed at optimal doses.\n   2. Rapidly declining kidney function with a reduction in estimated GFR of \\>5 mL\u002Fmin per 1.73m2 per year and average 24-hour ambulatory systolic blood pressure ≥140 mmHg despite ≥3 antihypertensive drugs including a diuretic, if tolerated, and each prescribed at optimal doses.\n   3. Hospital admissions with acute decompensated heart failure (≥2 hospitalizations for heart failure or ≥1 hospitalizations for sudden, \"flash\" pulmonary edema) with no obvious explanations such as nonadherence, left ventricular ejection fraction \\\u003C40%, or valvular heart disease and average 24-hour ambulatory systolic blood pressure ≥140 mmHg despite ≥3 antihypertensive drugs including a diuretic, if tolerated, and each prescribed at optimal doses.\n\nAll 24-hour ambulatory blood pressure monitorings are performed after nurse-administered medication.\n\nExclusion Criteria:\n\n* Unable to provide informed consent.\n* Treatment-resistant heart failure episodes presumed caused by renovascular disease.\n* Rapidly declining kidney function\u002Facute kidney failure approaching the need for dialysis presumed caused by renovascular disease.\n* Fibromuscular dysplasia or other non-atherosclerotic renal artery stenosis known to be present prior to randomization.\n* Pregnancy or unknown pregnancy status in female of childbearing potential.\n* Kidney size \\\u003C7 cm (pole to pole length) supplied by target vessel.\n* Previous kidney transplant.\n* Previous PTRA treatment.\n* Presence of a renal artery stenosis not amenable for treatment with a stent.\n\nPatients who are not eligible for randomization but treated with renal artery stenting outside the protocol are followed according to the DAN-PTRAII protocol in order to account for all PTRA treatments performed in Denmark in the study period.\n\nPatients treated with renal artery stenting without randomization in the study period include patients with:\n\n1. Treatment-resistant heart failure episodes presumed caused by renovascular disease.\n2. Rapidly declining kidney function\u002Facute kidney failure approaching the need for dialysis presumed caused by renovascular disease.\n3. At least one of the listed high-risk clinical syndromes AND one or more significant atherosclerotic renal artery stenoses defined as a stenosis of 50-69% by catheter-based angiography with:\n\n   * a mean translesional gradient of ≥10 mm Hg, or\n   * a systolic translesional gradient of ≥20 mm Hg, or\n   * a renal fractional flow reserve (Pd\u002FPa) of ≤0.8",{"count":58,"type":21},80,"INTERVENTIONAL",[61],"NA","The goal of this clinical trial is to document a beneficial effect of percutaneous transluminal renal angioplasty (PTRA) of atherosclerotic renal artery stenosis in high-risk patients selected according to the criteria used in the DAN-PTRA study. The main questions the trial aims to answer are if renal artery stenting compared with optimal medical treatment alone has beneficial effects on:\n\n* Blood pressure\n* Kidney function\n* Hospitalizations for heart failure",[31,64,32,65,66],"Renovascular Hypertension With Renal Failure","Renal Artery Stenosis Atherosclerotic","Percutaneous Transluminal Angioplasty","2026-04-20",{"date":69,"type":40},"2026-04-23",{"date":71,"type":40},"2023-06-26",{"date":73,"type":21},"2027-06-01",{"name":46,"class":47}]